(Press-News.org) HER2-positive metastatic biliary tract cancer (BTC) is a rare and aggressive cancer with limited treatment options
Final results from the HERIZON-BTC-01 clinical trial, the largest study of a HER2-targeted drug in BTC, show zanidatamab has clinically meaningful responses
The targeted therapy demonstrated durable responses, longer survival and tumor shrinkage in some BTC patients
Zanidatamab was granted accelerated FDA approval for treating HER2-positive BTC in Nov. 2024, based on these trial results
Zanidatamab, a bispecific HER2-targeted antibody, delivered clinically meaningful and durable responses for patients with HER2-positive biliary tract cancer (BTC), according to final results from the HERIZON-BTC-01 clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
In this clinical trial, zanidatamab demonstrated an objective response rate of 41.3% and a median duration of response of 15.5 months, while patients whose tumors showed strongest levels of HER2 overexpression experienced even greater benefit – a 51.6% response rate and a median duration of response of 18.1 months.
Results from this trial, led by Shubham Pant, M.D., professor of Gastrointestinal Medical Oncology and Investigational Cancer Therapeutics, were published in JAMA Oncology. Initial trial results were first reported in The Lancet Oncology in June 2023.
“The observed objective response rate, prolonged duration of response, and consistent activity in IHC3+ tumors underscores HER2 as a valid therapeutic target in biliary tract cancer and support the emerging role of zanidatamab in the treatment paradigm,” Pant said.
What is the significance of the HERIZON-BTC-01 trial results?
Unresectable or metastatic biliary tract cancer (BTC) is a rare, aggressive cancer and has very limited treatment options once standard therapies stop working. These findings represent the largest HER2-targeted clinical database in BTC and provide the longest follow-up reported to date.
In a cohort of 80 patients, those who responded to zanidatamab reported meaningful improvements in their symptoms, particularly in pain levels. Many experienced either reductions or stabilization of pain compared with their baseline, indicating the treatment not only controlled tumor growth but also helped alleviate disease-related discomfort. In addition, patients who remained on the study long enough to complete follow-up assessments showed higher rates of overall symptom control.
What are the implications of this trial for patients with biliary tract cancers?
Zanidatamab is a bispecific antibody that binds to two distinct sites on the HER2 receptor, enabling it to more effectively inhibit cancer cell growth and promote immune-mediated elimination of tumor cells compared with traditional HER2-targeted therapies.
These trial results directly supported the Food and Drug Administration (FDA) accelerated approval of zanidatamab for adults with previously treated, unresectable or metastatic IHC3+ biliary tract cancer. The durability and safety profile suggest zanidatamab has strong therapeutic potential for this difficult-to-treat cancer.
***
This trial was supported by was supported by BeOne Medicines, Jazz Pharmaceuticals, and Zymeworks. A full list of collaborating authors and their disclosures can be found with the paper in JAMA Oncology.
END
HER2-targeted therapy shows promising results in rare bile duct cancers
2025-11-25
ELSE PRESS RELEASES FROM THIS DATE:
Metabolic roots of memory loss
2025-11-25
For decades, scientists have known that what harms the body often harms the brain. Conditions such as obesity, high blood pressure and insulin resistance strain the body’s vascular and metabolic systems. Over time, that stress can speed up cognitive decline and increase the risk of Alzheimer’s disease.
Now, researchers at Arizona State University and their collaborators report that these effects may begin far earlier than expected. In young adults with obesity, the team identified biological markers of inflammation, liver stress ...
Clinical outcomes and in-hospital mortality rate following heart valve replacements at a tertiary-care hospital
2025-11-25
Background and objectives
Mechanical valve replacement is a primary treatment for rheumatic heart disease, yet prosthesis-related adverse outcomes remain underreported in India. This study aimed to examine the in-hospital mortality rate among patients who underwent prosthetic heart valve replacement surgeries in the past five years.
Methods
A retrospective analysis of 221 rheumatic heart disease patients (2019–2023) who underwent aortic valve replacement (AVR), mitral valve replacement (MVR), or double valve replacement (DVR) was conducted. Comorbidities (hypertension, type-2 diabetes mellitus) and valve origin (Indian ...
Too sick to socialize: How the brain and immune system promote staying in bed
2025-11-25
“I just can’t make it tonight. You have fun without me.” Across much of the animal kingdom, when infection strikes, social contact shuts down. A new study details how the immune and central nervous systems implement this sickness behavior.
It makes perfect sense that when we’re battling an infection, we lose our desire to be around others. That protects them from getting sick and lets us get much needed rest. What hasn’t been as clear is how this behavior change happens.
In the research published Nov. 25 in Cell, scientists at The Picower Institute for Learning and Memory of MIT and collaborators used multiple methods to demonstrate ...
Seal milk more refined than breast milk
2025-11-25
Researchers at the University of Gothenburg have discovered that milk from grey seals in the Atlantic Ocean may be more potent than breast milk. An analysis of seal milk found approximately 33 per cent more sugar molecules than in breast milk. Many of these sugars are unique and may pave the way for even better infant formula for babies.
During the 17 days that grey seal pups suckle, they need to get their digestive systems up and running and build up an immune system to protect them against diseases and other dangers they may encounter in the North Atlantic. It is reasonable to suspect that their mother's milk is extremely refined to accomplish this task. ...
Veterans with cardiometabolic conditions face significant risk of dying during extreme heat events
2025-11-25
Veterans living in California who have cardiometabolic conditions such as diabetes and high blood pressure experience significantly higher risk of dying during heat waves compared to cooler days, UCLA-led research finds.
The study, to be published in the peer-reviewed JAMA Network Open, demonstrates the danger that heat waves can pose for people with heart disease and risk factors for heart disease, whether or not they are veterans, said Dr. Evan Shannon, assistant professor-in-residence at the David Geffen School of Medicine at UCLA and the study’s lead author. Veterans are particularly vulnerable to these heat events because they tend to be older, ...
How plants search for nutrients
2025-11-25
What makes plants tolerant to nutrient fluctuations? An international research team led by the Technical University of Munich (TUM) and involving the Leibniz Institute of Plant Genetics and Crop Plant Research (IPK) has investigated this question on the micronutrient boron. The researchers analyzed 185 gene data sets from the model plant Arabidopsis. Their goal is to then be able to transfer the findings to the important crop plant rapeseed.
Boron is one of the key micronutrients for the growth and fertility of many plants. However, extreme weather events reduce the availability of this nutrient: drought reduces boron uptake, ...
Prefrontal cortex reaches back into the brain to shape how other regions function
2025-11-25
Vision shapes behavior and, a new study by MIT neuroscientists finds, behavior and internal states shape vision. The research, published Nov. 25 in Neuron, finds in mice that via specific circuits, the brain’s executive control center, the prefrontal cortex, sends tailored messages to regions governing vision and motion to ensure that their work is shaped by contexts such as the mouse’s level of arousal and whether they are on the move.
“That’s the major conclusion of this paper: There are targeted projections for targeted ...
Much-needed new drug approved for deadliest blood cancer
2025-11-25
Biomedical research that began at the University of Virginia School of Medicine has yielded a much-needed new treatment for patients with the deadliest form of blood cancer.
The federal Food and Drug Administration has approved the drug ziftomenib for patients with recurring or treatment-resistant acute myeloid leukemia who have a mutation in the NPM1 gene. The new medication, taken by mouth once daily, offers a potential treatment for patients who otherwise have no good options.
The drug arose from many years of research by Jolanta Grembecka, PhD, and Tomasz Cierpicki, PhD, who began the ...
American College of Lifestyle Medicine publishes official position on lifestyle medicine as a framework for delivery of high-value, whole-person care
2025-11-25
The American College of Lifestyle Medicine (ACLM) has published a position paper calling for the implementation of lifestyle medicine as a high-value care solution that delivers on the Quintuple Aim—better health outcomes, higher patient and clinician satisfaction, greater health equity, and lower costs.
The paper includes five position statements asserting that lifestyle medicine—a rapidly growing medical specialty focused on evidence-based lifestyle interventions to treat, reverse and prevent chronic disease—offers a scalable and sustainable approach to address the nation’s ...
Hospital infections associated with higher risk of dementia
2025-11-25
BUFFALO, NY — November 25, 2025 — A new research paper was published in Volume 17, Issue 10 of Aging-US on October 13, 2025, titled “Hospitalization with infections and risk of Dementia: a systematic review and meta-analysis.”
This large-scale meta-analysis, led by first author Wei Yu Chua from the National University of Singapore and corresponding author Eng-King Tan from the National Neuroscience Institute and Duke-NUS Medical School in Singapore, shows that adults hospitalized ...